NCM Capital Management LLC Reduces Stake in Amgen Inc. $AMGN

NCM Capital Management LLC lowered its holdings in Amgen Inc. (NASDAQ:AMGN) by 3.7% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 2,347 shares of the medical research company’s stock after selling 90 shares during the quarter. NCM Capital Management LLC’s holdings in Amgen were worth $731,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. First Pacific Financial lifted its stake in shares of Amgen by 304.5% in the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 67 shares during the period. Pinney & Scofield Inc. purchased a new position in shares of Amgen in the 4th quarter valued at approximately $26,000. Global Wealth Strategies & Associates lifted its stake in shares of Amgen by 1,388.9% in the 1st quarter. Global Wealth Strategies & Associates now owns 134 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 125 shares during the period. Heck Capital Advisors LLC purchased a new position in shares of Amgen in the 4th quarter valued at approximately $36,000. Finally, South Plains Financial Inc. purchased a new position in shares of Amgen in the 4th quarter valued at approximately $37,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Mizuho raised their target price on Amgen from $235.00 to $280.00 and gave the company a “neutral” rating in a research note on Wednesday, May 7th. Morgan Stanley raised their target price on Amgen from $330.00 to $333.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. William Blair restated an “outperform” rating on shares of Amgen in a research note on Tuesday, June 24th. UBS Group lowered their target price on Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a research note on Wednesday, August 6th. Finally, Guggenheim assumed coverage on Amgen in a research note on Tuesday, May 20th. They issued a “neutral” rating and a $288.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $303.76.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares of the company’s stock, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the sale, the senior vice president directly owned 8,162 shares of the company’s stock, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their position. The disclosure for this sale can be found here. 0.76% of the stock is currently owned by company insiders.

Amgen Stock Down 0.7%

Shares of NASDAQ:AMGN opened at $293.72 on Monday. The stock has a fifty day simple moving average of $293.43 and a two-hundred day simple moving average of $293.14. The stock has a market capitalization of $158.13 billion, a price-to-earnings ratio of 24.02, a PEG ratio of 2.53 and a beta of 0.49. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $339.17. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.28 by $0.74. The business had revenue of $9.18 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.2%. Amgen’s dividend payout ratio (DPR) is presently 77.84%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.